Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

NCT05360615 is registered in ClinicalTrials.gov with Chulalongkorn University as lead sponsor.

NCT NCT05360615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05360615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
Lead sponsor
Chulalongkorn University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 1, 2022
Completion date
July 1, 2027
Enrollment
147 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

empagliflozin in post aki stage 2-3